Kobayashi Pharmaceutical Co., Ltd.

4967

JP3301100008

Personal Products

Market Closed - Japan Exchange Other stock markets 07:00:00 05/07/2024 BST			5-day change	1st Jan Change
5,308 ^JPY	-1.74%		+1.63%	-21.83%

06-24	Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100	CI
05-24	Japan companies hog the spotlight as hedge funds tout their top Asia picks	RE

Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100

June 23, 2024

Latest news about Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100	06-23	CI
Japan companies hog the spotlight as hedge funds tout their top Asia picks	05-24	RE
A second Kobayashi Pharma Japan factory inspected over deaths	03-31	RE
Kobayashi factory searched over deaths possibly linked to supplements	03-30	RE
Kobayashi Pharmaceutical Recalls 'Beni-Koji' Supplement Following Report of Death, Kidney Damage	03-27	MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023.	11-08	CI
Kobayashi Pharmaceutical Co., Ltd's Equity Buyback announced on November 7, 2023, has closed with 1,924,600 shares, for ¥11,999.88 million.	11-07	CI
Kobayashi Pharmaceutical Co., Ltd. acquired Focus Consumer Healthcare, LLC.	06/10/23	CI
Kobayashi Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Organ Technologies Inc announced that it has received funding from Kobayashi Pharmaceutical Co., Ltd.	09/02/23	CI
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 1, 2022.	02/11/22	CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 1, 2022, has closed with 1,150,602 shares, representing 1.49% for ¥9,991.92 million.	01/11/22	CI
Kobayashi Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million.	01/11/22	CI
Kobayashi Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	31/10/22	CI
Kobayashi Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year 2022	04/08/22	CI
UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy	03/03/22	MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 28, 2021.	14/02/22	CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on October 28, 2021, has expired with 883,300 shares, representing 1.13% for ¥7,999.54 million.	09/02/22	CI
Kobayashi Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares, representing 1.28% for ?8,000 million.	28/10/21	CI
Kobayashi Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	27/10/21	CI
Kobayashi Pharmaceutical Co., Ltd. acquired Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.	29/09/20	CI
Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) added to S&P Japan Mid Cap 100	22/06/20	CI
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 31, 2019.	21/05/19	CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 31, 2019 has expired with 909,500 shares for ¥7,999.28 million.	15/05/19	CI
Kobayashi Pharmaceutical Co., Ltd. acquired Meitanhonpo.Co.,Ltd.	13/05/19	CI

Chart Kobayashi Pharmaceutical Co., Ltd.

Duration

Period

Chart Kobayashi Pharmaceutical Co., Ltd.

More charts

KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.

Sector

Personal Products

Calendar

07/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Kobayashi Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5,308 JPY

Average target price

5,941 JPY

Spread / Average Target

+11.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Personal Products

	1st Jan change	Capi.
KOBAYASHI PHARMACEUTICAL CO., LTD.	-21.83%	2.46B
PROCTER & GAMBLE COMPANY	+12.74%	390B
COLGATE-PALMOLIVE COMPANY	+21.75%	79.62B
HINDUSTAN UNILEVER LIMITED	-4.36%	71.68B
ESTEE LAUDER	-27.28%	38.13B
KENVUE INC.	-14.96%	35.06B
BEIERSDORF	+0.41%	33.01B
ESSITY AB	+9.36%	18.3B
GODREJ CONSUMER PRODUCTS LIMITED	+21.45%	16.83B
DABUR INDIA LIMITED	+8.84%	12.87B

Other Personal Products